Podcasts about nonsteroidal

Nonsteroidal anti-inflammatory drugs (NSAIDs) are the commonly used drugs in reducing pain, inflammation, and fever. And the question that rises is whether it is possible to relieve back pain without relying on NSAIDs. And, yes, it is possible to find relief from back pain without relying on NSAIDs. Alternative methods for managing back pain include physical therapy, exercise, stretching, heat or cold treatment, and mindfulness practices like yoga or meditation. In some cases, lifestyle changes such as improving posture, reducing weight, or managing stress can also help alleviate pain. Working with a healthcare practitioner can be very beneficial if the pain is persistent. Home care Home care remedies that can help relieve back pain, including heat and cold therapy, and gentle and low-impact exercises, like swimming and walking, can help strengthen the muscles supporting your spine to improve flexibility. Maintaining a straight posture while sitting and standing and a suitable sleeping position can prevent additional strain on your back. Also, gentle massage on the affected area can reduce muscle tension risks of future injury. Chiropractic Care Chiropractic care includes spinal adjustments by a professional to realign the spine, relieve nerve pressure, and reduce the pain. You can also embrace soft tissue therapy techniques such as massage to help alleviate tension and improve circulation, thus reducing back pain. In addition, chiropractors often provide activities that strengthen muscles to support the spine, enhancing flexibility and promoting better posture. Comprehensive care with movement The simple activities we engage in daily, including walking and stretching, can help with back pain without the need for NSAIDs. The comprehensive therapy combines physical activities to strengthen the core, improve flexibility, and promote proper posture. Such activities include low-impact ones like swimming, walking, and stretching regularly. However, you must be mindful of tai chi and yoga practices to alleviate back strain. ·         Decompression therapy  Using a specialized decompression table, a chiropractor will apply gentle traction to create intervertebral spaces for the compressed disks to retract and ease pressure on the surrounding nerves. Please do not lose this golden opportunity for your long-sought back pain and sciatica relief. Please book an appointment with our chiropractor for the best back pain and sciatica remedies. Long-term use of NSAIDs is not good as such drugs may lead to complications such as gastrointestinal complications, kidney issues, cardiovascular risks such as a surge in the risk of stroke and heart attack, and reduced effectiveness in treating chronic pain. Instead of using NSAIDs for back pain and sciatica relief, you can use physical therapy, proper home and work ergonomics, heat or cold therapies, and lifestyle modification. And if you need more guidance on how you can relieve back pain without NSAIDs and understanding why using NSAIDs long-term is not good, talk to Dr. Jason Jones at our Chiropractic office in Elizabeth City, NC, for assistance!

New treatment alert! The FDA recently approved Tapinarof, applied as a cream, for kids 2 years and up. We ask Dr. Leon Kircik from Icahn School of Medicine, NY, who led the clinical trials about the safety, efficacy and side effects of Tapinarof. And because we are parents too, we ask: How quickly does it work? Can you start/stop it as needed? How easy will it be to access? And more. If you like our podcast, please consider supporting it with a tax deductible donation. Research discussedTapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and ChildrenMaximal usage trial of tapinarof cream 1% once daily in pediatric patients down to 2 years of age with extensive atopic dermatitisTapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trialsTapinarof cream in the treatment of atopic dermatitis in children and adults a systematic review and meta-analysisEfficacy and safety of Ruxolitinib, Crisaborole, and Tapinarof for mild-to-moderate atopic dermatitis: a Bayesian network analysis of RCTs

Please visit answersincme.com/YTP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in cardiology and nephrology discuss the latest evidence and guidance on the use of nonsteroidal mineralocorticoid receptor antagonist (MRA) for the treatment of cardio-renal-metabolic conditions. Upon completion of this activity, participants should be better able to: Identify patients with type 2 diabetes (T2D) who are at high risk for chronic kidney disease (CKD) progression and cardiovascular events; Outline the clinical implications of updated CKD guidelines regarding the use of nonsteroidal MRA therapy in patients with T2D and CKD; and Describe the latest evidence on the use of nonsteroidal MRA therapies in individuals with cardio-renal-metabolic conditions.

In this episode of Derms and Conditions, host James Q. Del Rosso, DO, is joined by Omar Noor, MD, co-owner of Rao Dermatology in New York, NY, who shares his expertise on integrating nonsteroidal topical therapies into psoriasis treatment. As systemic therapies continue to advance, Dr Noor emphasizes the enduring importance of topical treatments with a focus on the aryl hydrocarbon receptor agonist, tapinarof. They begin by discussing the role of newer nonsteroidal options for psoriasis like roflumilast and tapinarof, highlighting their benefits in contrast to corticosteroids, which, despite their effectiveness, can carry significant adverse effects. Dr Noor describes how he incorporates these treatments into his practice, starting with topical steroids in some cases and transitioning to nonsteroidal options as needed. Dr Noor's approach allows for flexible treatment plans tailored to each patient's response. Dr Noor goes on to note that his experience with tapinarof aligns with emerging clinical data, showing effectiveness in challenging areas like the scalp with minimal adverse effects. He highlights that while contact dermatitis was observed in trials, it is rare in his practice, and proper patient education helps mitigate risks. They then discuss the remittive effect that some patients achieve with tapinarof, thanks to its mechanism of action as an aryl hydrocarbon receptor agonist. This contrasts with corticosteroids, which are often seen as temporary solutions. He encourages health care providers to take the time to engage thoughtfully with patients, recognizing their investment in their care and the value of personalized attention and education. Tune in to this episode for valuable insights on optimizing psoriasis treatment and improving patient care through effective use of nonsteroidal therapies and enhanced communication strategies.

In the podcast with Dr. Kelly StDenis, she delves into the new guidelines from AAFP regarding the chronic use of NSAIDs in cats. Dr. StDenis discusses the importance of these guidelines in managing feline pain and the potential risks associated with long-term NSAID usage in cats. She provides insights into alternative pain management strategies and emphasizes the need for careful monitoring when using NSAIDs in feline patients.

https://darienchiropractor.com/darien-ct-leaky-gut-explained/Do you know what a Leaky Gut is? Do you have any of the following health issues? Digestive issues: This may include bloating, gas, diarrhea, and irritable bowel syndrome (IBS)-like symptoms. Food sensitivities: Advocates of the leaky gut theory propose that the increased permeability of the intestine allows larger particles to enter the bloodstream, potentially triggering immune reactions and food sensitivities. Fatigue: Some people claim to experience fatigue as a result of leaky gut, though fatigue is a common symptom in many health conditions. Joint pain: Joint pain and inflammation are sometimes linked to leaky gut Skin problems: Conditions such as eczema and acne have been suggested to be associated with leaky gut by some proponents. Autoimmune diseases: There is a theoretical link between increased intestinal permeability and autoimmune diseases, as the theory suggests that leaked particles may trigger an immune response Here are some factors that have been proposed to contribute to leaky gut: Dietary factors: Certain dietary components, such as a high intake of refined sugars, saturated fats, and processed foods, may contribute to inflammation and affect the integrity of the intestinal lining. Gut dysbiosis: Imbalance in the gut microbiota, known as dysbiosis, has been suggested as a potential factor. Disruptions in the balance of beneficial and harmful bacteria in the gut may influence intestinal permeability. Chronic stress: Prolonged stress may have an impact on the gut and its functions. Stress hormones, such as cortisol, could potentially affect the integrity of the intestinal barrier. Nonsteroidal anti-inflammatory drugs (NSAIDs): Long-term use of NSAIDs, such as ibuprofen, has been associated with increased intestinal permeability in some studies. Excessive alcohol consumption: Alcohol can contribute to inflammation and damage the intestinal lining, potentially increasing permeability. Environmental factors: Exposure to environmental toxins and pollutants has been proposed as a potential contributor to leaky gut Core Health Darien might be able to help you with a leaky gut. Call 203-656-3636 to schedule a consultation with Dr. McKay Thanks for watching! This podcast welcomes your feedback here are several ways to reach out to me. If you have a topic you would like to hear about send me a message. I appreciate your listening. Dr. Brian Mc Kayhttps://twitter.com/DarienChiro/https://www.facebook.com/ChiropractorBrianMckayhttps://chiropractor-darien-dr-brian-mckay.business.sitehttps://podcasts.apple.com/us/podcast/not-just-chiropractor-for-stamford-darien-norwalk-new/id1503674397?uo=4Core Health Darien-Dr.Brian Mc Kay 551 Post RoadDarien CT 06820203-656-363641.0833695 -73.46652073GMP+87 Darien, Connecticuthttps://youtu.be/WpA__dDF0O041.0834196 -73.46423349999999https://darienchiropractor.comhttps://darienchiropractor.com/darien/darien-ct-understanding-pain/Find us on Social Mediahttps://chiropractor-darien-dr-brian-mckay.business.site https://www.youtube.com/channel/UCNHc0Hn85Iiet56oGUpX8rwhttps://docs.google.com/spreadsheets/d/1nJ9wlvg2Tne8257paDkkIBEyIz-oZZYy/edit#gid=517721981https://goo.gl/maps/js6hGWvcwHKBGCZ88https://www.youtube.com/my_videos?o=Uhttps://www.linkedin.com/in/darienchiropractorhttps://www.facebook.com/ChiropractorBrianMckayhttps://sites.google.com/view/corehealthdarien/https://sites.google.com/view/corehealthdarien/home

Professor Riccardo Asero joins Professor Marcus Maurer to offer advice on the use of non-steroidal anti-inflammatory drugs (NSAID) in people with chronic spontaneous urticaria (CSU). The experts discuss risk assessment and strategies to avoid respiratory and cutaneous hypersensitivity reactions in people who require these common medications to manage comorbidities. Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here. Utilise the following external links to access additional resources relating to the topics discussed in this episode: Nonsteroidal anti-inflammatory drugs hypersensitivity in chronic spontaneous urticaria in the light of its pathogenesis and Progress in understanding hypersensitivity reactions to nonsteroidal anti-inflammatory drugs. Access additional resources by signing up to Medthority and to be notified for future ‘All Things Urticaria' podcast episodes! For more information about the UCARE/ACARE network and its activities, please visit: UCARE Website, UCARE LevelUp Program, ACARE Website, UCARE 4U Website, UDAY Website, CRUSE Control App and CURE Registry.

What does maturing in the gym mean to you? How have you changed as you've gone from noob to advanced?    That the biggest dudes typically aren't the scariest or most intimidating. For the most part they're the biggest of homies No pain no gain is only good to an extent...knowing your body and how far to push is more important than keeping up with someone else.In my youth I pushed too hard, injured myself, lost most gains, went back and said "congrats, you're stronger" Keeping it at 90% consistently is way better than 110% and needing a break or dealing with pain. Been there done that. Spend good amount of time on flexibility, mobility and warming up now. That you don't need to go all the way to muscular failure on every set to get great results. What I mean is that you stop 1-2 RIR instead of going all the way to the max on every set. I think you should go all the way to failure on the last set of whatever exercise you're doing Do you prefer training in a group or alone? Do you feel like you get the same workout when you are chatting it up between sets? Have you ever trained with a partner who kept you on track during the workout where you weren't resting too much between sets? Do you prefer training alone in a gym setting vs alone in a garage gym setting (Big Z, “I train alone because it is harder”)   Recovery - let's rank each modality Get A Massage. Eat Dark-Colored Fruits. Eat Leafy Greens & Cruciferous Veggies Foam Rolling Do Hot/Cold Therapy Get Extra Zinc Take Post-Workout Protein Eat High-Quality Protein At Every Meal. Active recovery - Non-strenuous aerobic or physical activity, such as walking, swimming, or yoga Hyperbaric oxygen therapy Nonsteroidal anti-inflammatory drugs Compression garments Electromyostimulation Red-light therapy Sleep Eating enough Hydration BCAAs or Electrolytes Mobility/stretching  

Overview Platelets Normal Value Range Pathophysiology Special considerations Elevated platelet levels Decreased platelet levels Nursing Points General Normal value ranges 100,000 – 450,000/mcL Also known as – Thrombocytes Pathophysiology Formed from Megakaryocyte Formed from bone marrow Produces 1000-3000 platelets Injury occurs at site Collagen releases activators Thrombocytes activate “sticky fingers”, which allow them to bind together. Travel to site (along with other clotting factors) Adhere to site, increase stimulation for other PLT, until clot is formed with fibrin Special considerations Use a lavender top tube (EDTA) Often sent in CBC Abnormal lab values Elevated platelets (thrombocytosis) Cancers Absence of a spleen Breaks down platelets Birth control Polycythemia vera Overproduction of cells Treatment via bloodletting, medications or hydration Decreased platelets (thrombocytopenia) ITP (Idiopathic thrombocytopenic purpura) Autoimmune disease Medications Hemorrhage Treated with transfusion Leukemia Treated with chemotherapy/radiation Medications Some diuretics Nonsteroidal anti-inflammatory drugs (NSAIDs) Ranitidine Some antibiotics Assessment Assess for signs of petechia (small purplish blemishes, indicating bleeding) Therapeutic Management Control and stop hemorrhage Replace platelets via transfusion Consider stopping or changing medications that cause thrombocytopenia Nursing Concepts Lab Values Clotting Patient Education For patients who have bleeding disorders, instruct patients to be cautious of injury. If patient has thrombocytopenia, instruct patient to seek emergency treatment in the event of bleeding that does not stop. **DISCLAIMER – The video states that the normal value of platelets is 100,000 – 400,000 cells/mcL. The correct information is 100,000 – 450,000 cells/mcL.

George L. Bakris, MD, MA - Step-by-Step: Setting a Course for Managing CKD and T2DM With Nonsteroidal MRAs

George L. Bakris, MD, MA - Step-by-Step: Setting a Course for Managing CKD and T2DM With Nonsteroidal MRAs

George L. Bakris, MD, MA - Step-by-Step: Setting a Course for Managing CKD and T2DM With Nonsteroidal MRAs

George L. Bakris, MD, MA - Step-by-Step: Setting a Course for Managing CKD and T2DM With Nonsteroidal MRAs

George L. Bakris, MD, MA - Step-by-Step: Setting a Course for Managing CKD and T2DM With Nonsteroidal MRAs

George L. Bakris, MD, MA - Step-by-Step: Setting a Course for Managing CKD and T2DM With Nonsteroidal MRAs

George L. Bakris, MD, MA - Step-by-Step: Setting a Course for Managing CKD and T2DM With Nonsteroidal MRAs

George L. Bakris, MD, MA - Step-by-Step: Setting a Course for Managing CKD and T2DM With Nonsteroidal MRAs

Heartburn, the burning sensation in your chest caused by acid reflux, affects millions worldwide. While over-the-counter medications and prescription drugs may offer relief, many people look for natural home remedies, which leads them to wonder, “Do essential oils help with heartburn?” In this article, I'll review what causes heartburn, how essential oils may help alleviate some symptoms, and how to prevent it. Prevalence In the United States alone, it is estimated that approximately 60 million adults experience heartburn at least once a month, with 15 million suffering daily.El-Serag, H. B., Sweet, S., Winchester, C. C., & Dent, J. (2014). Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut, 63(6), 871-880. Men are more likely to experience heartburn and gastroesophageal reflux disease (GERD) than women, likely because of men's hormones, lifestyles, diets, and alcohol consumption.Nilsson, M., Johnsen, R., Ye, W., Hveem, K., & Lagergren, J. (2003). Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. JAMA, 290(1), 66-72. The prevalence of heartburn and GERD increases with age. One study found that GERD symptoms increased from 10.8% in individuals aged 18-24 to 21.8% in those aged 65-74.Locke, G. R., Talley, N. J., Fett, S. L., Zinsmeister, A. R., & Melton, L. J. (1997). Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology, 112(5), 1448-1456. This increase may be attributed to age-related changes in esophageal function and increased gastric acid secretion. Causes Heartburn occurs when stomach acid flows back into the esophagus, causing irritation and a burning sensation in the chest area. This condition, also known as acid reflux, can be triggered by obesity, smoking, certain medications, and consuming acidic, fatty, or spicy foods.Mayo Clinic. (2018). Heartburn. Retrieved from https://www.mayoclinic.org/diseases-conditions/heartburn/symptoms-causes/syc-20373223 Lifestyle habits like stress and lack of sleep can also contribute to heartburn episodes. I want to highlight obesity and medications, as they're often overlooked or ignored as causal factors. Obesity Obesity is a significant risk factor for the development of heartburn and gastroesophageal reflux disease (GERD). Obesity leads to heartburn and GERD through: Increased intra-abdominal pressure: Obesity, particularly central or abdominal obesity, increases intra-abdominal pressure. This increased pressure puts pressure on the stomach, which can cause the lower esophageal sphincter (LES) to weaken or open, allowing stomach acid to flow back into the esophagus, resulting in heartburn.Pandolfino, J. E., El-Serag, H. B., Zhang, Q., Shah, N., Ghosh, S. K., & Kahrilas, P. J. (2006). Obesity: a challenge to esophagogastric junction integrity. Gastroenterology, 130(3), 639-649. Hormonal changes: Adipose tissue in obese individuals can cause hormonal changes, including the release of adipokines and cytokines, which have been linked to inflammation and impaired LES function.Hampel, H., Abraham, N. S., & El-Serag, H. B. (2005). Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Annals of Internal Medicine, 143(3), 199-211. Esophageal motility disorders: Obesity may also be associated with esophageal motility disorders, which can contribute to developing heartburn and GERD.El-Serag, H. B. (2008). Role of obesity in GORD-related disorders. Gut, 57(3), 281-284. Medications Several medications can contribute to heartburn by weakening the LES, irritating the esophageal lining, or slowing gastric emptying. Some common medications associated with heartburn include: Nonsteroidal anti-inflammatory drugs (NSAIDs): NSAIDs, such as aspirin, ibuprofen, and naproxen, can irritate the esophageal lining and increase the risk of heartburn.Wolfe, M. M., Lichtenstein, D.

Today's Speaker: Sahil Parag, DO IM Resident, PGY-3 Objectives: 1. Understand the mechanism of action of Finerenone, and how it differs from currently used mineralocorticoid receptor antagonists 2. Identify patients that may benefit from addition of this medication 3. Understand adverse effects and monitoring for these patients 4. Identify the recommendations for specific population that may benefit from use of this medication along with current guidelines 5. Understand patients who this medication would be contraindicated despite have ckd and diabetes

Did you know that, beyond chronic kidney disease (CKD), patients with type 2 diabetes (T2D) are also at high risk for developing cardiovascular complications and even death? Credit available for this activity expires: 1/24/2024 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/986818?ecd=bdc_podcast_libsyn_mscpedu

This episode is brought to you by TrackableMed, the place to go to help grow your new patient base.  This episode is also brought to you by Heron Therapeutics. Please see full Prescribing Information, including Boxed Warning or visit www.ZYNRELEF.com. Dr. William B. Kurtz is a board-certified, fellowship-trained orthopedic surgeon who specializes in hip and knee replacements at Tennessee Orthopaedic Alliance. Dr. Kurtz holds a bachelor's degree in mechanical engineering from Rice University. He graduated medical school from The University of Texas Southwestern Medical School at Dallas with Alpha Omega Alpha honors distinction. He completed a residency in orthopedic surgery at Vanderbilt University Medical Center, followed by a subspecialty fellowship in adult reconstructive joint surgery at New England Baptist Hospital in Boston. Topics include: -His role in Ortho Founders, a place where orthopreneurs can pitch their innovations and gain feedback from other leaders in orthopedics. -Dr. Will Kurtz is President of Tennessee Orthopaedic Alliance, a group of 106 physicians. He is also a board member in Ortho Forum, whose members comprise 100 private practice groups across the U.S. to share data analysis and best practices on revenue cycle management and ancillary revenue streams. -He's done over 10,000 Conformis knees, made specifically for the patient. Dr. Kurtz breaks down the difference between Conformis personalized knees and a standard total knee, which comes off-the-shelf. -We discuss his recent business case study in Journal Orthopaedic Experience and Innovation, Value Creation vs Value Capture in Orthopedics. Find out more about Dr. Will Kurtz here. Also, find out more about Zynrelef here: ZYNRELEF utilizes a novel synergistic mechanism of action that combines bupivacaine with a low dose of meloxicam to overcome the challenges of the inflammatory process at the surgical site. ZYNRELEF is the first and only extended-release dual-acting local anesthetic™ (DALA™) and delivers 72 hours of postoperative pain relief via a single needle-free application. It has been clinically proven to better manage pain than standard of care bupivacaine HCl solution over 72 hours and to significantly reduce opioid utilization following surgery. -ZYNRELEF was initially approved by the FDA in May 2021 and in December 2021, the FDA approved an expansion of ZYNRELEF's indication. -Limitations of Use: Safety and efficacy have not been established in highly vascular surgeries, such as intrathoracic, large multilevel spinal, and head and neck procedures. WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS See full prescribing information for complete boxed warning. • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use • ZYNRELEF is contraindicated in the setting of coronary artery bypass graft (CABG) surgery • NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events ZYNRELEF is contraindicated for: • Patients with a known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to any local anesthetic agent of the amide-type, NSAIDs, or to any of the other components of ZYNRELEF OR history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients • Patients undergoing obstetrical paracervical block...

This episode is brought to you by TrackableMed, the place to go to help grow your new patient base. This episode is brought to you by Heron Therapeutics. Please see full Prescribing Information, including Boxed Warning or visit www.ZYNRELEF.com. Dror Paley, MD, FRCSC, is the founder (2009) and director of the Paley Institute in West Palm Beach, Florida. Prior to that he was the founder (2001) and director of the Rubin Institute for Advanced Orthopedics, and the director of the International Center for Limb Lengthening (ICLL) at Sinai Hospital of Baltimore from 2001-2009. He was the Chief of Pediatric Orthopedics at the University of Maryland in Baltimore 1987-2001. He is internationally recognized for his expertise in limb lengthening and reconstruction. Topics include: -We hear why he went into orthopedics and then chose the niche path for limb lengthening. Dr. Paley trained under the guidance of Professor Ilizarov of Russia (Ilizarov method) and Professor Debastiani of Italy (Orthofix method). In 1986, he introduced the Ilizarov method to the United States and Canada. Since that time, he has performed more than 20,000 limb lengthening and reconstruction-related procedures. Patients come to his Institute from more than 100 countries. -Dr. Paley reviews how limb lengthening works and breaks down this complex topic for anyone to understand, including the different types of limb lengthening to include the use of external fixators, often called cages, and remote controlled internal limb lengthening. Find out more about Dr. Dror Paley here. Also, find out more about Zynrelef here: ZYNRELEF utilizes a novel synergistic mechanism of action that combines bupivacaine with a low dose of meloxicam to overcome the challenges of the inflammatory process at the surgical site. ZYNRELEF is the first and only extended-release dual-acting local anesthetic™ (DALA™) and delivers 72 hours of postoperative pain relief via a single needle-free application. It has been clinically proven to better manage pain than standard of care bupivacaine HCl solution over 72 hours and to significantly reduce opioid utilization following surgery. -ZYNRELEF was initially approved by the FDA in May 2021 and in December 2021, the FDA approved an expansion of ZYNRELEF's indication. -Limitations of Use: Safety and efficacy have not been established in highly vascular surgeries, such as intrathoracic, large multilevel spinal, and head and neck procedures. WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS See full prescribing information for complete boxed warning. • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use • ZYNRELEF is contraindicated in the setting of coronary artery bypass graft (CABG) surgery • NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events ZYNRELEF is contraindicated for: • Patients with a known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to any local anesthetic agent of the amide-type, NSAIDs, or to any of the other components of ZYNRELEF OR history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients • Patients undergoing obstetrical paracervical block anesthesia OR coronary artery bypass graft (CABG) surgery WARNINGS AND PRECAUTIONS include –

This episode is brought to you by Heron Therapeutics. Please see full Prescribing Information, including Boxed Warning or visit www.ZYNRELEF.com. This episode is also brought to you by TrackableMed, grow your new patients. We have the one and only Dr. Brian Cole for this episode. Dr. Brian Cole is an orthopedic sports medicine surgeon at Midwest Orthopaedics at Rush and a Professor of Orthopaedics, Anatomy and Cell Biology at Rush University Medical Center. Dr. Cole is Managing Partner of Midwest Orthopaedics and is the Department's Associate Chairman and the Section Head of the Cartilage Research and Restoration Center. He's one of the most prolific and most influential sports medicine surgeons in the world. Dr. Cole is the head team physician for the Chicago Bulls and co-team physician for the Chicago White Sox. He's a member of every society for sports medicine orthopedics with a vast history of experience with a passion for education. This is one you're going to enjoy! Topics include:-He discusses what made him decide to become a physician and the influence going into orthopedics, including residency at the Hospital for Special Surgery at Cornell Medical Center, and a Sports Medicine fellowship at the University of Pittsburgh. Dr. Cole talks about how he made his way back to Chicago after fellowship at Midwest Orthopaedics at Rush and helping to build the cartilage restoration program. -He talks about the "private-demic" model of Rush, running it as a private practice with the benefits of being in the academic world. It's a private independent practice that fosters entrepreneurialism. -Dr. Cole has a passion for fellowships and can hear his devotion for the importance of mentorships. He discusses how it's essential to positively influence the next generation through fellowships. -We also hear about what is his work//life balance like with all of his responsibilities. Find out more about Dr. Brian Cole here. Also, find out more about Zynrelef here: ZYNRELEF utilizes a novel synergistic mechanism of action that combines bupivacaine with a low dose of meloxicam to overcome the challenges of the inflammatory process at the surgical site. ZYNRELEF is the first and only extended-release dual-acting local anesthetic™ (DALA™) and delivers 72 hours of postoperative pain relief via a single needle-free application. It has been clinically proven to better manage pain than standard of care bupivacaine HCl solution over 72 hours and to significantly reduce opioid utilization following surgery. -ZYNRELEF was initially approved by the FDA in May 2021 and in December 2021, the FDA approved an expansion of ZYNRELEF's indication. -Limitations of Use: Safety and efficacy have not been established in highly vascular surgeries, such as intrathoracic, large multilevel spinal, and head and neck procedures. WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS See full prescribing information for complete boxed warning. • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use • ZYNRELEF is contraindicated in the setting of coronary artery bypass graft (CABG) surgery • NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events ZYNRELEF is contraindicated for: • Patients with a known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to any local anesthetic agent of the amide-type, NSAIDs,

This episode is brought to you by Heron Therapeutics. Please see full Prescribing Information, including Boxed Warning or visit www.ZYNRELEF.com. Dr. Alexander Sah joins for this episode from Sah Orthopaedic Associates at the Institute for Joint Restoration in Fremont, CA. He is an orthopedic surgeon, specializing in minimally invasive hip and knee replacements, knee arthroscopy, as well as complex hip and knee revision surgeries.   Topics include: -We hear about his patient-first emphasis with thorough and compassionate care. He has a deep commitment to the Bay Area community going home to practice at the same hospital he was born, Washington Hospital. -We discuss his family influence in becoming a physician with his uncles, grandfather, and father practicing medicine.  He completed his orthopedic training at Harvard in Boston and specialized fellowship training in minimally invasive and revision hip and knee surgery at Rush University in Chicago. -Dr. Sah has built his brand with minimally invasive surgery where patients seek him out as a destination practice at Sah Orthopaedic Associates. -We talk ambulatory surgery centers (ASCs) and answer these questions: Is it safe? Is it cost effective? What is the patient satisfaction? -Dr. Sah discusses his interest in orthopedic research and remains active in publishing articles and presenting this work at national meetings. He worked with Heron Therapeutics as an expert in total knee replacement as the company developed the pivotal clinical study program to help inform FDA submissions and meet FDA guidelines for ZYNRELEF. ZYNRELEF utilizes a novel synergistic mechanism of action that combines bupivacaine with a low dose of meloxicam to overcome the challenges of the inflammatory process at the surgical site. ZYNRELEF is the first and only extended-release dual-acting local anesthetic™ (DALA™) and delivers 72 hours of postoperative pain relief via a single needle-free application. It has been clinically proven to better manage pain than standard of care bupivacaine HCl solution over 72 hours and to significantly reduce opioid utilization following surgery. -ZYNRELEF was initially approved by the FDA in May 2021 and in December 2021, the FDA approved an expansion of ZYNRELEF's indication. -Limitations of Use: Safety and efficacy have not been established in highly vascular surgeries, such as intrathoracic, large multilevel spinal, and head and neck procedures. WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS See full prescribing information for complete boxed warning. • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use • ZYNRELEF is contraindicated in the setting of coronary artery bypass graft (CABG) surgery • NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events ZYNRELEF is contraindicated for: • Patients with a known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to any local anesthetic agent of the amide-type, NSAIDs, or to any of the other components of ZYNRELEF OR history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients • Patients undergoing obstetrical paracervical block anesthesia OR coronary artery bypass graft (CABG) surgery WARNINGS AND PRECAUTIONS include -

This episode is brought to you by Heron Therapeutics. Please see full Prescribing Information, including Boxed Warning or visit www.ZYNRELEF.com. If you like happy vibes with a positive patient track record, we've got the orthopedic surgeon for you. Meet Dr. Atiba Jackson from Dayton, OH. He is a Board-Certified Orthopedic Sports Medicine specialist, with fellowship training in sports medicine so he can provide the highest level of care for this brand of injuries. He treats complex shoulder injuries including rotator cuff, labrum, SLAP tears, instability, and dislocations. In addition to treating difficult knee injuries, including ACL tears, ligamentous injuries, meniscus tears, cartilage injuries, he also treats elbow injuries and performs elbow arthroscopy. He cares for arthritis patients, performing replacements of the shoulder, knee, and hip. Topics include: -His family influence in becoming an orthopedic surgeon, as his father is a family practice doctor. Dr. Jackson has strong family ties and we hear the importance of family in this episode. He also became a teenage parent, overcame the adversity and remained focused on becoming an orthopedic surgeon. -Dr. Atiba Jackson helps train the clinical and surgical techniques at the Grandview Orthopedic Residency (DO) program. We hear about the post-grant research position they've developed for those in a bridge year to help them become more of a competitive applicant. -He has social media following for promoting his private practice, Orthopedic Associates, and educating his patients. Dr. Jackson looks like Usher and uses it to his advantage when creating engaging posts. Find out more about Dr. Atiba Jackson here. Also, find out more about Zynrelef here: ZYNRELEF utilizes a novel synergistic mechanism of action that combines bupivacaine with a low dose of meloxicam to overcome the challenges of the inflammatory process at the surgical site. ZYNRELEF is the first and only extended-release dual-acting local anesthetic™ (DALA™) and delivers 72 hours of postoperative pain relief via a single needle-free application. It has been clinically proven to better manage pain than standard of care bupivacaine HCl solution over 72 hours and to significantly reduce opioid utilization following surgery. -ZYNRELEF was initially approved by the FDA in May 2021 and in December 2021, the FDA approved an expansion of ZYNRELEF's indication. -Limitations of Use: Safety and efficacy have not been established in highly vascular surgeries, such as intrathoracic, large multilevel spinal, and head and neck procedures. WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS See full prescribing information for complete boxed warning. • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use • ZYNRELEF is contraindicated in the setting of coronary artery bypass graft (CABG) surgery • NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events ZYNRELEF is contraindicated for: • Patients with a known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to any local anesthetic agent of the amide-type, NSAIDs, or to any of the other components of ZYNRELEF OR history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients • Patients undergoing obstetrical paracervical blo...

In this episode, I review an article on alternatives to Ibuprofen. This episode is sponsored by McNeese Construction. You can also read this episode on our blog at https://yopistudio.blogspot.com/2022/03/natural-alternatives-for-ibuprofen.html To keep this podcast going please feel free to donate at www.paypal.me/yopistudio If you would like to read more on this topic or any other previous topics, you can do so by checking out our blog at https://yopistudio.blogspot.com/ Feel free to see what we are up to by following us at:  https://twitter.com/Dauricee https://parler.com/profile/Daurice/ https://www.facebook.com/yopistudio/ https://www.facebook.com/LouisianaEntertainmentAssociation/ To listen to the podcast, watch creative videos and skits go to https://www.youtube.com/channel/UCvn6tns6wKUwz9xZw11_vAQ/videos Interested in projects Daurice has worked on in the movie industry you can check it out at www.IMDb.com under Daurice Cummings. Please add us to your RSS Feed, & iTunes, iHeart, Spotify, Stitcher, Google Pod, Sound Cloud, and our favorite Podbean! For comments or questions, you can reach us at yopi@post.com To read more about today's topic check out the references below. References: https://www.forbes.com/2004/12/13/cx_mh_1213faceoftheyear.html?sh=7432b7776d57 https://www.reuters.com/article/us-painkillers-risks/high-doses-of-common-painkillers-increase-heart-attack-risks-idUSBRE94S1FV20130529?feedType=RSS&feedName=healthNews https://www.greenmedinfo.com/blog/ibuprofen-kills-more-pain-so-what-alternatives https://www.greenmedinfo.com/blog/ibuprofen-can-stop-your-heart-31-increase-cardiac-arrest-risk https://www.greenmedinfo.com/blog/ibuprofen-deadly-vioxx https://www.greenmedinfo.com/toxic-ingredient/ibuprofen https://www.greenmedinfo.com/substance/arnica https://www.greenmedinfo.com/article/topical-treatment-arnica-effective-ibuprofen-hand-osteoarthritis https://www.greenmedinfo.com/substance/ginger https://www.greenmedinfo.com/article/ginger-effective-mefenamic-acid-and-ibuprofen-relieving-pain-women-primary-dys https://www.greenmedinfo.com/substance/turmeric https://www.greenmedinfo.com/article/efficacy-and-safety-curcuma-domestica-extracts-compared-ibuprofen-patients-kne https://www.greenmedinfo.com/substance/thyme https://www.greenmedinfo.com/article/thymus-vulgaris-least-effective-ibuprofen-reducing-severity-pain-and-spasm-pri https://www.greenmedinfo.com/substance/omega-3-fatty-acids https://www.greenmedinfo.com/article/omega-3-fatty-acids-are-effective-alternative-ibuprofen-reducing-arthritic-pai https://www.greenmedinfo.com/substance/cinnamon https://www.greenmedinfo.com/blog/cinnamon-beats-ibuprofen-pain-study-reveals-2 https://www.greenmedinfo.com/pharmacological-action/anti-inflammatory-agents https://www.greenmedinfo.com/pharmacological-action/analgesics https://www.greenmedinfo.com/blog/powerful-aspirin-alternative-grows-trees-1 https://www.greenmedinfo.com/toxic-ingredient/non-steroidal-anti-inflammatory-drugs-nsaids Fitzgerald, G.A. (2001). The coxibs, selective inhibitors of cyclooxygenase-2. New England Journal of Medicine, 345, 433-442. Fitzgerald, G.A. (2004). Coxibs and cardiovascular disease. The New England Journal of Medicine, 351(17), 1709-1711.  Coxib and traditional NSAID Trialists' (CNT) Collaboration et al. (2013). Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet, 382(9849), 769-779. doi: 10.1016/S0140-6736(13)60900-9 Mukherjee, D., Nissen, S.E., & Topol, E.J. (2001). Risk of Cardiovascular Events Associated With Selective COX-2 Inhibitors. Journal of the American Medical Association, 286(8), 954-959. doi:10.1001/jama.286.8.954doi:10.1001/jama.286.8.954 Singh, D. (2004). Merck withdraws arthritis drug worldwide. The British Medical Journal, 329. doi: link.  Berenson et al. (2004). Despite Warnings, Drug Giant Took Long Path to Vioxx Recall. The New York Times. Retrieved from here.  Tanne, J.H. (2008). Merck used ghostwriters and selective data in Vioxx publications, JAMA says. British Medical Journal, 336(849). doi: link.  Steenhuysen, J. (2009). Vioxx risks could have been detected earlier: study. Reuters. Retrieved from here. Willson, D. (2011). Merck to Pay $950 Million Over Vioxx. The New York Times. Retrieved from here. The Associated Press. (2010). Supreme Court Allows Investors to Sue Merck Over Vioxx. The New York Times. Retrieved from here.  ConsumerAffairs. (2004). The Food and Drug Administration (FDA) estimates that Vioxx may have contributed to 27,785 heart attacks. Retrieved from here.  Kearney et al. (2006). Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drug increase the risk of atherothrombosis? Meta-analysis of randomised trials. British Medical Journal, 332, 1302-1308.  McGettigan, P., & Henry, D. (2011). Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Medicine, 8, e1001098.  Trelle et al. (2011). Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. British Medical Journal, 342, c7086.  Sostres, C., Gargallo, C.J., & Lanas, A. (2013). Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Research Therapies, 15(Suppl 3), S3.   Marlicz et al. (2014). Nonsteroidal anti-inflammatory drugs, proton pump inhibitors, and gastrointestinal injury: contrasting interactions in the stomach and small intestine. Mayo Clinic Proceedings, 89(12), 1699-1709.  Maiden et al. (2005). A quantitative analysis of NSAID-induced small bowel pathology by capsule endoscopy. Gastroenterology, 128(5), 1172-1178. Goldstein et al. (2005). Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole and placebo. Clinical Gastroenterology and Hepatology, 3(2), 133-141.  Shiotani et al. (2010). Randomized, double-blind pilot study of gnarly geranylacetone versus placebo in patients taking low dose enteric-coated aspirin: low-dose aspirin-induced small bowel damage. Scandinavian Journal of Gastroenterology, 45(3), 292-298.  Caunedo-Alvarez et al. (2010). Macroscopic small bowel mucosal injury caused by chronic non steroidal anti-inflammatory drugs (NSAIDs) use as assessed by capsule endoscopy. Rev Esp Enferm Dig, 102(2), 80-85. Kent, T.H., Cardelli, R.M., & Stamler, F.W. (1969). Small intestinal ulcers and intestinal flora in rats given indomethacin. American Journal of Pathology, 54(2), 237-249. Uejima et al. (1996). Role of intestinal bacteria in ileal ulcer formation in rats treated with a non steroidal anti-inflammatory drug. Microbiology and Immunology, 40(8), 553-560.  Watanbe et al. (2008). Non-steroidal anti-inflammatory drug-induced intestinal damage is Toll like 4 receptor dependent. Gut, 57(2), 181-187. Fasano, A. (2012). Leaky gut and autoimmune disease. Clinical Reviews in Allergy and Immunology, 42(1), 71-78.  Lanza, F.L., Chan, F.K., & Quigley, E.M. (2009). Practice parameters committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. American Journal of Gastroenterology, 104(2), 728-238.  Bhatt et al. (2008). ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of anti platelet therapy and NSAID use: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation, 118(18), 1894-1909.  American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis and Rheumatology, 46(2), 328-346.  Wallace et al. (2011). Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology, 141(4), 1314-1322.   Endo et al. (2011). Efficacy of Lactobacillus casei treatment on small bowel injury in chronic low-dose aspirin users: a pilot randomized controlled study. Journal of Gastroenterology, 46(7), 894-905.  Bhala et al. (2013). Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. The Lancet, 382(9894), 769-779.  Montenegro et al. (2014). Non steroidal anti-inflammatory drug induced damage on lower gastro-intestinal tract: is there an involvement of microbiota? Current Drug Safety, 9(3), 196-204. Ozgoli, G., Goli, M., & Moattar, F. (2009). Comparison of effects of ginger, mefenamic acid, and ibuprofen on pain in women with primary dysmenorrhea. Journal of Alternative and Complementary Medicine, 15(2), 129-132. doi: 10.1089/acm.2008.0311. Salmalian et al. (2014). Comparative effect of thymus vulgaris and ibuprofen on primary dysmenorrhea: A triple-blind clinical study. Caspian Journal of Internal Medicine, 5(2), 82-88.  Levy et al. (2009). Flavocoxid is as effective as naproxen for managing the signs and symptoms of osteoarthritis of the knee in humans: a short-term randomized, double-blind pilot study. Nutrition Research, 29(5), 298-304. doi: 10.1016/j.nutres.2009.04.003. Conrozier et al. (2014). A Complex of Three Natural Anti-inflammatory Agents Provides Relief of Osteoarthritis Pain. Alternative Therapies in Health and Medicine, 20(Suppl 1), 32-37.  Chiu et al. (2016). Effects of Intravenous and Oral Magnesium on Reducing Migraine: A Meta-analysis of Randomized Controlled Trials. Pain Physician, 19(1), E97-E112. Diener et al. (2005). Efficacy and safety of 6.25 mg tid feverfew CO2‐extract (MIG‐99) in migraine prevention—a randomized, double‐blind, multicentre, Placebo‐controlled study. Cephalalgia, 25(11), 1031–1041. Lipton et al. (2004). Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology, 63(12), 2240-2244.  Shara, M., & Stohs, S.J. (2015). Efficacy and Safety of White Willow Bark (Salix alba) Extracts. Physiotherapy Research, 29(8), 1112-1116. doi: 10.1002/ptr.5377. Vlachojannis, J.E., Cameron, M., & Chrubasik, S. (2009). A systematic review on the effectiveness of willow bark for musculoskeletal pain. Phytotherapy Research, 23(7), 897-900. doi: 10.1002/ptr.2747. Wesolowska et al. (2006). Analgesic and sedative activities of lactucin and some lactucin-like guaianolides in mice. Journal of Ethnopharmacology, 107, 254-258. Gupta, S.K., & Ansari, S.H. (2005). Review on phytochemical and pharmacological aspects of Cichorium intybus L. Asian Journal of Chemistry, 17, 33-36. Tall et al. (2004). Tart cherry anthocyanins suppress inflammation-induced pain behavior in rat. Brain and Behavior Research, 153(1), 181-188. Seeram et al. (2001). Cyclooxygenase inhibitory and antioxidant cyanidin glycosides in cherries and berries. Phytomedicine, 8(5), 362-369. Kuehl et al. (2010). Efficacy of tart cherry juice in reducing muscle pain during running: a randomized controlled trial. Journal of International Society of Sports Nutrition, 7, 17. doi: 10.1186/1550-2783-7-17. Illich, I. (1974). Medical Nemesis: The Expropriation of Health. New York: Pantheon Books. Capone et al. (2004). Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects.          

CME credits: 0.25 Valid until: 28-02-2023 Claim your CME credit at https://reachmd.com/programs/cme/nonsteroidal-mras-latest-evidence-of-cardiorenal-protection-in-ckd-and-t2d/13298/ Achieving optimal outcomes when treating patients with chronic kidney disease (CKD) in type 2 diabetes (T2D) remains a challenge due to the multidisciplinary response needed to prevent progressive renal dysfunction. Low screening rates and underdiagnosis impede early interventions. On the other hand, early diagnosis and regular screening of CKD in T2D set the stage for clinicians to optimize drug therapy to prevent progression to end-stage renal disease while aggressively managing comorbid T2D and other CKD risk factors.

CME credits: 0.25 Valid until: 28-02-2023 Claim your CME credit at https://reachmd.com/programs/cme/nonsteroidal-mras-latest-evidence-of-cardiorenal-protection-in-ckd-and-t2d/13298/ Achieving optimal outcomes when treating patients with chronic kidney disease (CKD) in type 2 diabetes (T2D) remains a challenge due to the multidisciplinary response needed to prevent progressive renal dysfunction. Low screening rates and underdiagnosis impede early interventions. On the other hand, early diagnosis and regular screening of CKD in T2D set the stage for clinicians to optimize drug therapy to prevent progression to end-stage renal disease while aggressively managing comorbid T2D and other CKD risk factors.

How To Ease Your HERNIATED DISC PAIN In As Little As 7 Days… Even if you´ve tried everything else and failed! https://www.herniateddiscsecrets.com/01 How do you fix a herniated lumbar disc? Nonsurgical treatment may include: 1.Rest. One to 2 days of bed rest will usually help relieve back and leg pain. 2.Nonsteroidal anti-inflammatory medications (NSAIDs). Medications such as ibuprofen or naproxen can help relieve pain. 3.Physical therapy. 4.Epidural steroid injection.

Nonsteroidal anti-inflammatory drugs (NSAIDs) are the first-line medication for acute low back pain (LBP). It is unclear if the choice of NSAID impacts outcomes. We compared ibuprofen, ketorolac, and diclofenac for the treatment of acute, nonradicular LBP.

Shifting the Treatment Paradigm in Type 2 Diabetes and CKD: The Role of Nonsteroidal MRAs

Shifting the Treatment Paradigm in Type 2 Diabetes and CKD: The Role of Nonsteroidal MRAs

Shifting the Treatment Paradigm in Type 2 Diabetes and CKD: The Role of Nonsteroidal MRAs

Shifting the Treatment Paradigm in Type 2 Diabetes and CKD: The Role of Nonsteroidal MRAs

Shifting the Treatment Paradigm in Type 2 Diabetes and CKD: The Role of Nonsteroidal MRAs

Shifting the Treatment Paradigm in Type 2 Diabetes and CKD: The Role of Nonsteroidal MRAs

Shifting the Treatment Paradigm in Type 2 Diabetes and CKD: The Role of Nonsteroidal MRAs

Shifting the Treatment Paradigm in Type 2 Diabetes and CKD: The Role of Nonsteroidal MRAs

Nonsteroidal anti-inflammatory drugs (NSAIDs), such as high-dose aspirin, Ibuprofen (Advil, Motrin, Midol) and Naproxen (Aleve, Naprosyn) are the best OTC drugs for reducing inflammation. https://recoverypartnernetwork.com/drug/opioid/over-the-counter-substance-abuse

Go online to PeerView.com/CWT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in nephrology discuss emerging evidence for improving outcomes and preventing chronic kidney disease (CKD) progression using nonsteroidal mineralocorticoid receptor antagonists. Upon completion of this activity, participants should be better able to: Apply current guidance consistent with the latest recommendations for screening, diagnosis, and treatment of patients with or at risk of developing CKD, Describe the interrelationships among CKD and other common cardiometabolic comorbidities, Evaluate the role and clinical potential of novel nonsteroidal mineralocorticoid receptor antagonists in providing renoprotection and preventing disease progression in patients diagnosed with CKD.

Go online to PeerView.com/CWT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in nephrology discuss emerging evidence for improving outcomes and preventing chronic kidney disease (CKD) progression using nonsteroidal mineralocorticoid receptor antagonists. Upon completion of this activity, participants should be better able to: Apply current guidance consistent with the latest recommendations for screening, diagnosis, and treatment of patients with or at risk of developing CKD, Describe the interrelationships among CKD and other common cardiometabolic comorbidities, Evaluate the role and clinical potential of novel nonsteroidal mineralocorticoid receptor antagonists in providing renoprotection and preventing disease progression in patients diagnosed with CKD.

Go online to PeerView.com/CWT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in nephrology discuss emerging evidence for improving outcomes and preventing chronic kidney disease (CKD) progression using nonsteroidal mineralocorticoid receptor antagonists. Upon completion of this activity, participants should be better able to: Apply current guidance consistent with the latest recommendations for screening, diagnosis, and treatment of patients with or at risk of developing CKD, Describe the interrelationships among CKD and other common cardiometabolic comorbidities, Evaluate the role and clinical potential of novel nonsteroidal mineralocorticoid receptor antagonists in providing renoprotection and preventing disease progression in patients diagnosed with CKD.

Go online to PeerView.com/CWT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in nephrology discuss emerging evidence for improving outcomes and preventing chronic kidney disease (CKD) progression using nonsteroidal mineralocorticoid receptor antagonists. Upon completion of this activity, participants should be better able to: Apply current guidance consistent with the latest recommendations for screening, diagnosis, and treatment of patients with or at risk of developing CKD, Describe the interrelationships among CKD and other common cardiometabolic comorbidities, Evaluate the role and clinical potential of novel nonsteroidal mineralocorticoid receptor antagonists in providing renoprotection and preventing disease progression in patients diagnosed with CKD.

Go online to PeerView.com/CWT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in nephrology discuss emerging evidence for improving outcomes and preventing chronic kidney disease (CKD) progression using nonsteroidal mineralocorticoid receptor antagonists. Upon completion of this activity, participants should be better able to: Apply current guidance consistent with the latest recommendations for screening, diagnosis, and treatment of patients with or at risk of developing CKD, Describe the interrelationships among CKD and other common cardiometabolic comorbidities, Evaluate the role and clinical potential of novel nonsteroidal mineralocorticoid receptor antagonists in providing renoprotection and preventing disease progression in patients diagnosed with CKD.

Go online to PeerView.com/CWT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in nephrology discuss emerging evidence for improving outcomes and preventing chronic kidney disease (CKD) progression using nonsteroidal mineralocorticoid receptor antagonists. Upon completion of this activity, participants should be better able to: Apply current guidance consistent with the latest recommendations for screening, diagnosis, and treatment of patients with or at risk of developing CKD, Describe the interrelationships among CKD and other common cardiometabolic comorbidities, Evaluate the role and clinical potential of novel nonsteroidal mineralocorticoid receptor antagonists in providing renoprotection and preventing disease progression in patients diagnosed with CKD.

Go online to PeerView.com/CWT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in nephrology discuss emerging evidence for improving outcomes and preventing chronic kidney disease (CKD) progression using nonsteroidal mineralocorticoid receptor antagonists. Upon completion of this activity, participants should be better able to: Apply current guidance consistent with the latest recommendations for screening, diagnosis, and treatment of patients with or at risk of developing CKD, Describe the interrelationships among CKD and other common cardiometabolic comorbidities, Evaluate the role and clinical potential of novel nonsteroidal mineralocorticoid receptor antagonists in providing renoprotection and preventing disease progression in patients diagnosed with CKD.

Go online to PeerView.com/CWT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in nephrology discuss emerging evidence for improving outcomes and preventing chronic kidney disease (CKD) progression using nonsteroidal mineralocorticoid receptor antagonists. Upon completion of this activity, participants should be better able to: Apply current guidance consistent with the latest recommendations for screening, diagnosis, and treatment of patients with or at risk of developing CKD, Describe the interrelationships among CKD and other common cardiometabolic comorbidities, Evaluate the role and clinical potential of novel nonsteroidal mineralocorticoid receptor antagonists in providing renoprotection and preventing disease progression in patients diagnosed with CKD.

Go online to PeerView.com/CWT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in nephrology discuss emerging evidence for improving outcomes and preventing chronic kidney disease (CKD) progression using nonsteroidal mineralocorticoid receptor antagonists. Upon completion of this activity, participants should be better able to: Apply current guidance consistent with the latest recommendations for screening, diagnosis, and treatment of patients with or at risk of developing CKD, Describe the interrelationships among CKD and other common cardiometabolic comorbidities, Evaluate the role and clinical potential of novel nonsteroidal mineralocorticoid receptor antagonists in providing renoprotection and preventing disease progression in patients diagnosed with CKD.

Go online to PeerView.com/CWT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in nephrology discuss emerging evidence for improving outcomes and preventing chronic kidney disease (CKD) progression using nonsteroidal mineralocorticoid receptor antagonists. Upon completion of this activity, participants should be better able to: Apply current guidance consistent with the latest recommendations for screening, diagnosis, and treatment of patients with or at risk of developing CKD, Describe the interrelationships among CKD and other common cardiometabolic comorbidities, Evaluate the role and clinical potential of novel nonsteroidal mineralocorticoid receptor antagonists in providing renoprotection and preventing disease progression in patients diagnosed with CKD.

Pain can be incredibly inconvenient. But what we seem to forget is that pain is our body’s way of alerting us to a problem. Or it can be part of the natural healing process. This is not to say that chronic pain can’t be incredibly debilitating. However, we need to stop reaching for that cheap bottle of over the counter anti-inflammatories. They are doing more harm than good. Welcome to Fatal Conveniences™ This is a bite-sized segment that parallels The Darin Olien Show. In these segments, we get into society's Fatal Conveniences™. I define these as the things we may be doing because the world we live in makes us believe we have to. These things save us time and trick us into thinking they're actually good for us. But it's those same things that are breaking down our health, and the health of the environment around us. I've spent most of my adult life obsessively researching these "conveniences." On every show, I pick one topic, and we dive into it. My goal is to make you more aware of these traps so that you can push back on them. Remember, it starts with you and the choices you make.  So, if you're willing to look at your world from a different perspective and make little tweaks that amount to big changes, then this segment is for you. Americans spend $50 Billion a year on Over the Counter (OTC) Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) When I say OTC NSAIDs, I’m talking about common painkillers like Advil (ibuprofen), Aleve, Naproxen and high-dose aspirin. All these drugs are easily found in pharmacies, grocery stores and even gas stations. They’re so commonly used that many of you probably have them stored in your purses or backpacks right now, just in case. We are trained to pop a couple of these pills at the first sign of a headache or any sort of pain. It’s as American as apple pie.  I’m here to tell you that this is a bad habit we need to break. These meds are doing way more harm than good. They’re tearing apart our stomach lining, messing with our body’s ability to produce antibodies and conditioning us to treat symptoms instead of addressing pain at the source. In this Fatal Conveniences™ segment, we go into the history of NSAIDs and how they’ve become our drug of choice. I get into the awful truth behind what they’re doing to our health. And of course, I give you a plethora of alternative options when it comes to pain relief. I’m not trying to knock the seriousness of chronic pain, guys. I just want you to deal with it in ways that aren’t counterproductive to your health. Take back your power, and turn to plants. Other topics in this segment: The number one cause of bleeding stomach ulcers NSAIDs and the heart Pain’s role in healing The history of Bayer and big Pharma The risk to water and the environment from NSAIDs The reason for inflammation NSAIDs and the immune system The risks of NSAIDs on pregnancy and fertility Natural anti-inflammatory foods Healthy ways to deal with pain CBD Links & Resources: History of Felix Hoffman Facts about Bayer Effects of Nonsteroidal  Anti-Inflammatories at the Molecular Level FDA Beefs up Warning on NSAIDs NSAIDs: How Dangerous Are They For Your Heart? Study on Ibuprofen Time Magazine: Ibuprofen May Not Be as Safe as You Think 10 Foods That Fight Pain Netflix’ Down To Earth’ Official Trailer Download my amazing new lifestyle app and get 3 days free at 121Tribe.com Barukas Nuts 15% discount with code “DARIN” Want more great info on how to detoxify your life? Sign up for my Fatal Conveniences™ emailsThe Darin Olien Show is produced by the team at Must Amplify. If you’re looking to give a voice to your brand, and make sure that it’s heard by the right people, head to www.mustamplify.com/darin to see what Amplify can do for you.

Dr. Pastore discusses Dermatitis Herpetiformis - an autoimmune condition with skin rashes that is caused by the consumption of gluten.   He covers who is most at risk, what this autoimmune condition is, how to get properly diagnosed and the celiac disease connection.   Discussed:   Dermatitis Herpetiformis (DH) is NOT the same as celiac disease. The majority of those with DH also have celiac disease, however there are people that only have DH and not celiac disease, and vice versa.   DH is an autoimmune reaction where antibodies (IgA) are formed after the consumption of gluten, which travels in bloodstream and are deposited in skin. This signals a reaction that creates itchy/blistering skin or bumps, resembles herpes-like lesions.   DH is misdiagnosed 95% of the time for eczema.   The prominent sign that it is DH and not eczema is that rashes will occur on both sides of body - typically around the knees, scalp, buttocks, elbows.    DH is diagnosed via skin biopsy, as 20% of patients have normal blood and intestine testing for celiac. Most have no gastrointestinal issues.   If you or a relative had Hashimoto's thyroiditis, Grave's disease, Celiac disease, type 1 diabetes,  lupus, or Sjogren's syndrome and you have eczema-like rash, speak to your doctor about a skin biopsy.   Misdiagnosed DH patients that are prescribed Prednisone/topical corticosteroids creams can mask symptoms temporarily, then cause a rebound flare-up.   Consuming other food intolerances (besides gluten) can make DH worse.   A gluten free diet combined with the antibiotic dapsone (topical or orally) is the common treatment for DH. It can take up to 2 years for full skin recovery.   Iodine and Nonsteroidal anti-inflammatory drugs (NSAIDs) can also cause or worsen flares. Iodine is found in: cough medicine, iodized salt, shellfish, seaweed/kelp/nori, yogurt, milk, and iodine supplements.        

Association of Multimodal Pain Management Strategies with Perioperative Outcomes and Resource Utilization: A Population-based Study. Memtsoudis SG1, Poeran J, Zubizarreta N, Cozowicz C, Mörwald EE, Mariano ER, Mazumdar M. BACKGROUND: Multimodal analgesia is increasingly considered routine practice in joint arthroplasties, but supportive large-scale data are scarce. The authors aimed to determine how the number and type of analgesic modes is associated with reduced opioid prescription, complications, and resource utilization. METHODS: Total hip/knee arthroplasties (N = 512,393 and N = 1,028,069, respectively) from the Premier Perspective database (2006 to 2016) were included. Analgesic modes considered were opioids, peripheral nerve blocks, acetaminophen, steroids, gabapentin/pregabalin, nonsteroidal antiinflammatory drugs, cyclooxygenase-2 inhibitors, or ketamine. Groups were categorized into "opioids only" and 1, 2, or more than 2 additional modes. Multilevel models measured associations between multimodal analgesia and opioid prescription, cost/length of hospitalization, and opioid-related adverse effects. Odds ratios or percent change and 95% CIs are reported. RESULTS: Overall, 85.6% (N = 1,318,165) of patients received multimodal analgesia. In multivariable models, additions of analgesic modes were associated with stepwise positive effects: total hip arthroplasty patients receiving more than 2 modes (compared to "opioids only") experienced 19% fewer respiratory (odds ratio, 0.81; 95% CI, 0.70 to 0.94; unadjusted 1.0% [N = 1,513] vs. 2.0% [N = 1,546]), 26% fewer gastrointestinal (odds ratio, 0.74; 95% CI, 0.65 to 0.84; unadjusted 1.5% [N = 2,234] vs. 2.5% [N = 1,984]) complications, up to a -18.5% decrease in opioid prescription (95% CI, -19.7% to -17.2%; 205 vs. 300 overall median oral morphine equivalents), and a -12.1% decrease (95% CI, -12.8% to -11.5%; 2 vs. 3 median days) in length of stay (all P < 0.05). Total knee arthroplasty analyses showed similar patterns. Nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors seemed to be the most effective modalities used. CONCLUSIONS: While the optimal multimodal regimen is still not known, the authors' findings encourage the combined use of multiple modalities in perioperative analgesic protocols. DOI: 10.1097/ALN.0000000000002132

This episode of CRACKCast covers Rosen's Chapter 149, Aspirin and Nonsteroidal agents. You will become well-versed in the presentation of Salicylism and how to manage it. The episode also touches on NSAID overdose, with rare severe complications.

This episode of CRACKCast covers Rosen's Chapter 149, Aspirin and Nonsteroidal agents. You will become well-versed in the presentation of Salicylism and how to manage it. The episode also touches on NSAID overdose, with rare severe complications.

On this date in 1899, Bayer registered the name “Aspirin” as a trademark. Here are some things you might not have known about aspirin. Aspirin is also known as acetylsalicylic acid. People have been using willow and myrtle trees, both rich in salicylate for thousands of years to treat pain and fever. Aspirin is a non-steroidal anti-inflammatory drug, in the same class as ibuprofen and naproxen. It’s a pain reliever, fever reducer and it fights inflammation. It works by suppressing the production of prostaglandins and thromboxanes. Prostaglandins are involved in the transmission of pain information, modulation of the thermostat in the brain and inflammation. Thromboxanes are responsible for the gathering of platelets that cause blood clots, which can lead to heart attacks. It proved difficult and wasteful to extract salicylic acid from plants, but in 1860 Hermann Kolbe figured out how to synthisize it. The synthesized drug had many of the positive effects of aspirin, but had negatives including weakening of the heart, gastric irritation and an intense bitter taste. In 1897, Bayer chemist Felix Hoffmann began working on how to make salicylic acid less irritating. It’s thought he began his research because his father had suffered from the side effects of sodium salicylate used to treat rheumatism. Using existing research, he discovered a better method for creating acetylsalicylic acid. Bayer would credit Hoffman as the inventor of aspirin, when in reality he refined the process of making it. Testing of what would become known as aspirin was delayed by company bureaucracy. It would have to wait even longer because Bayer’s testing department was busy testing diacetylmorphine, which would be become better known as heroin. The name heroin is a reference to the quote “heroic” feelings it gave the testers. Eventually aspirin was tested and was found to have few of the side effects of its predecessors. When it came time to name the drug, there were two final options: aspirin and euspirin. Aspirin was derived from its chemical name in German: Acetylspirsäure. Euspirin had a similar origin, but included the prefix eu- meaning good, as in euphemism. Aspirin was originally sold in powder form. However, this made it difficult to prevent competitors from making confusingly similar products. So Bayer began pressing aspirin into standardized tablets. During World War I, Bayer had its American assets seized, including its name and logo. It was purchased by Sterling Products, Inc. After World War II, aspirin lost market share to new drugs like acetaminophen and ibuprofen. In the 1980s when both new drugs were available over the counter, aspirin had a small portion of the pain reliever market. It was hurt even further by the link of aspirin consumption by children to Reye’s Syndrome, a potentially fatal disease. Soon after, aspirin’s effectiveness at reducing heart attacks was brought to light and the drug regained its place as the top-selling pain reliever in the U.S. In 1994, Bayer purchased Sterling Products and regained use of its name, logo and products in the United States. Our question: What year was heroin made illegal in the United States? Today is Independence Day in Ghana. It’s unofficially Dentist’s Day, National Oreo Cookie Day, and National Frozen Food Day. It’s the birthday of illustrator Will Eisner, who was born in 1917; author Gabriel Garcia Marquez, who was born in 1927; and basketball player Shaquille O’Neal, who turns 45. Because our topic happened before 1960, we’ll spin the wheel to pick a year at random. This week in 1979, the top song in the U.S. was “I Will Survive” by Gloria Gaynor. The No. 1 movie was “The Deer Hunter,” while the novel “Chesapeake” by our man James Michener topped the New York Times Bestsellers list.  Weekly question: For which book, later turned into a movie, did James Michener win the 1948 Pulitzer Prize for fiction? Submit your answer at triviapeople.com/test and we’ll add the name of the person with the first correct answer to our winner’s wall … at triviapeople.com. We'll have the correct answer on Friday’s episode. Links Follow us on Twitter, Facebook or our website. Also, if you’re enjoying the show, please consider supporting it through Patreon.com Please rate the show on iTunes by clicking here. Subscribe on iOS: http://apple.co/1H2paH9  Subscribe on Android: http://bit.ly/2bQnk3m  Sources https://en.wikipedia.org/wiki/Aspirin https://en.wikipedia.org/wiki/History_of_aspirin https://en.wikipedia.org/wiki/Bayer https://en.wikipedia.org/wiki/Pulmonary_aspiration https://en.wikipedia.org/wiki/Paracetamol https://en.wikipedia.org/wiki/Nonsteroidal_anti-inflammatory_drug https://en.wikipedia.org/wiki/COX-2_inhibitor https://en.wikipedia.org/wiki/Antipyretic http://www.narconon.org/drug-information/heroin-timeline.html https://en.wikipedia.org/wiki/Anti-Heroin_Act_of_1924 https://en.wikipedia.org/wiki/March_6 https://www.checkiday.com/3/6/2017 http://www.biography.com/people/groups/born-on-march-06 http://www.bobborst.com/popculture/numberonesongs/?chart=us&m=3&d=6&y=1979&o= https://en.wikipedia.org/wiki/List_of_1979_box_office_number-one_films_in_the_United_States

Furry-Muscle Cast – 38 – Fall Is Coming! - September 1.      Introductions ·         Maximus Ursus – This bear is everywhere ·         Tonka Wolf – The mean fighting machine! Tonka Truck? ·         Tiptoe – Sexting! Not in THAT way. ·         Beastly Bahamut – Snowing eh? ·         Schredded Wolf – WTF?! Is he here? ·         Syn – Show white…it’s nice. ·         Jazz Wolf –Is he here? ·         Snowheart – What is this?!!? Cursedmarked ·         Tiberious – Working, Working, Working got to keep on cooking. ·         Zak – 5 Weeks of heck and a day of repeat of it.   2.      Topics A.    Mr. Olympia   MR. OLYMPIA Phil Heath Kai Greene Dennis Wolf Shawn Rhoden Dexter Jackson Ibrahim Fahim Justin Compton Steve Kuclo Branch Warren Mamdouh Elssbiay Juan Morel Roelly winklaar William Bonac Victor Martinez Jonathan Delarosa Evan Centopani Lionel Beyeke Cedric McMillan Johnnie Jackson Jojo Ntiforo Essa Obaid Fred Smalls   212 SHOWDOWN James Flex Lewis David Henry Kevin English Jose Raymond Eduardo Correa Sami Al Haddad Guy Cisternino Aaron Clark Charles Dixon Hidetada Yamagishi Mark Dugdale Raul Carrasco Ahmad Ahmad Baito Abbaspour Mboya Edwards         B.     Carpal Tunnel o   Wear proper supportive devices to prevent wrist flexion. o   Practice moderation during exercise. In most cases, the more difficult the resistance training exercise. o   Ice your wrists after resistance training workouts, it will reduce the inflammation that can occur as a result of the activity o   Refrain from doing weight-bearing wrist curls or any other exercises where you feel excessive pain in the wrist. o   Nonsteroidal anti-inflammatory medications such as ibuprofen reduce pain and inflammation. C.     Tiberious’ Center o   Proper form for the Big 3 (Bench, Squat, and Deadlift.) These lifts exist in bodybuilding as strongly as powerlifting, and there are a lot of myths and fears of injury when considering them.   D.    Emails 1.      From: NativeWolf @SchreddedWolf Questions: Do you believe Jay Culter is out of it finally? Why?   2.      From: CatKittyr @Tiptoe Questions: What time do you usually do cardio normally?   3.      From: Bullzbear @Tiberious Questions: Do you have any problems with spine problems?   E.     Closing Out: §  We can’t do the show without you, the listeners! §  Please take the time to rate us on iTunes or Thumbs us up at Stitcher Radio. §  You can email us at FMC@furry-muscle.org §  Have any questions or comments? Drop us a line at 571-208-BUFF (2833). §  Follow us on Twitter @FurryMuscleCast §  You can find show notes, pictures, links and many other materials at our main website http://www.furry-muscle.org §  Next Furry-Muscle Cast: October 10th.   Furry Thunder Dome: https://www.youtube.com/watch?v=8hkWpmJ29p0 Fursuite Dance Off: http://fursuittourney.livejournal.com/   Tiberious Links Deadlift - https://www.youtube.com/results?search_query=so+you+think+you+can+deadlift Bench Press - https://www.youtube.com/results?search_query=so+you+think+you+can+bench Squat - https://www.youtube.com/results?search_query=so+you+think+you+can+squat Back Arch - http://www.powerliftingtowin.com/wp-content/uploads/2014/02/bencharch-comparison.jpg                

Nonsteroidal anti-inflammatory drugs (NSAIDs) provide analgesia by altering the body's inflammatory response. However, when ingested in toxic amounts, severe clinical signs can be seen. The question remains, what NSAIDS are safe for dogs? What NSAIDS are safe for cats? What side effects should we monitor for in these patients? More importantly, how do we treat NSAID toxicosis? VetGirl answers all things NSAIDs in this veterinary podcast.

Nonsteroidal anti-inflammatory drugs (NSAIDs) provide analgesia by altering the body's inflammatory response. However, when ingested in toxic amounts, severe clinical signs can be seen. The question remains, what NSAIDS are safe for dogs? What NSAIDS are safe for cats? What side effects should we monitor for in these patients? More importantly, how do we treat NSAID toxicosis? VetGirl answers all things NSAIDs in this veterinary podcast.